Top Tweets for #ThyCSM
#ClinicalTrial EA3231, led by @LovaSunMD of @PennCancer, is testing #TargetedTherapy approaches for patients with #ThyroidCancer that has worsened during or after treatment. For more information: https://t.co/4276H54qPr #thycsm
Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer.
Read the full article. https://t.co/w77v0QKVpH
#thycsm
@MayoClinic Integrated Care Enables Treatment for Rare, Complex Cancer
#thycsm #oncology
https://t.co/sSckzHV39g
Our team recently attended the British Thyroid Association Annual Meeting, where we presented new research on radioiodine-refractory differentiated thyroid cancer (RAI-R DTC).
#thycsm
Circulating Tumor DNA as a Biomarker for Disease
Surveillance in Anaplastic #ThyroidCancer.
Read the full article. https://t.co/PWLrKXNJzK
#thycsm
An updated analysis on larotrectinib for patients with TRK fusion thyroid carcinoma showed compelling data on the agent’s efficacy and safety, including a high and durable response rate and a manageable safety profile. #thycsm #ASCO25 | @KimmelCancerCtr
https://t.co/pZ2xfTG2LJ
WATCH: Nicole A. Cipriani, MD, explores the clinical relevance of the BRAF p.V600E mutation in papillary thyroid carcinoma and its potential role in guiding treatment decisions. #thycsm | @nicolecipriani
https://t.co/unnKX4mLBN
An Italian study (NCT04031339) has found that patients with papillary thyroid carcinoma smaller than 1 cm typically experience more favorable outcomes compared with patients whose tumors are larger, particularly 1 year after surgery. #thycsm
https://t.co/vYoHHMI5KH
In a video, Francis P. Worden, MD, offers key takeaways for oncologists treating patients with radioidine-refractory differentiated thyroid cancer. #thycsm | @UMRogelCancer
https://t.co/MY624Km8vq
WATCH: Francis P. Worden, MD, discusses his key takeaways for other oncologists treating patients with radioidine-refractory differentiated thyroid cancer. #thycsm | @UMRogelCancer
@umichmedicine
https://t.co/fF6AQRvgcJ
WATCH: Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management. #thycsm | @BaptistHealthSF
https://t.co/uio5vd03jm
Learn about signs, symptoms and warning signs of #thyroidcancer from Jochen Lorch, MD, medical director of our Thyroid Cancer Program at @LurieCancer @NorthwesternMed. #thycsm
A medical oncologist weighs in on the thyroid cancer symptoms to never ignore.
Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer. #thycsm | @MassGeneralMDs
https://t.co/fnzcVW6e14
In this video, Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from other clinical trials. #thycsm
https://t.co/NSpkYm60Nb
Atezolizumab + targeted therapy demonstrated longer median overall survival compared with historic controls in patients with anaplastic thyroid cancer, according to findings from a phase 2 study. #thycsm
https://t.co/YO6FDgukoC
Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma https://t.co/C12DQuvFhy #thycsm #thyroidcancer #oncology #immunotherapy
The FDA granted traditional approval to selpercatinib for adult & pediatric patients aged 2 years & older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. #thycsm
https://t.co/YXp7WWT272
Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of. #thycsm | @BaptistHealthSF @BHCancerCare @MiamiCancerInst
https://t.co/RFsTcfb7SW
Long-Term Look at Selpercatinib in RET-Activated Thyroid Cancer https://t.co/xlmbAOf7T1 #thycsm #thyroidcancer #oncology
According to Lori J. Wirth, MD, one crucial shift of late has been with the growing ability to avoid over diagnosing clinically insignificant thyroid cancers. #THYCSM | @MGHCancerCenter
https://t.co/qsw9RuPGnp
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers